CNBG-Virogin Biotech (Shanghai) Ltd.
8 clinical trials · Sponsor
◉ Watch CNBG-Virogin Biotech (Shanghai) Ltd.
| Record | Firm | Date |
|---|---|---|
| Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma (NCT06124001) | CNBG-Virogin Biotech (Shanghai) Ltd. | 2023-11-30 |
| A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine (NCT06113731) | CNBG-Virogin Biotech (Shanghai) Ltd. | 2023-07-10 |
| Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma (NCT06746480) | CNBG-Virogin Biotech (Shanghai) Ltd. | 2022-03-19 |
| Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors (NCT04758897) | CNBG-Virogin Biotech (Shanghai) Ltd. | 2021-04-14 |
| Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer (NCT04806464) | CNBG-Virogin Biotech (Shanghai) Ltd. | 2021-03-16 |
Track CNBG-Virogin Biotech (Shanghai) Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.